Celldex Therapeutics, Inc.
CLDXDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
2dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
CLDX Earnings Report
EPS Est: $-1.04 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CLDX's past catalysts played out
Temozolomide
Glioblastoma
barzolvolimab
Prurigo Nodularis
Rindopepimut (CDX-110) with GM-CSF
Glioblastoma
CDX-110 with GM-CSF
Malignant Glioma
"Investigator's Choice" chemotherapy
Breast Cancer
CDX-011
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Advanced Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Temozolomide | Phase 3 | Glioblastoma | - | - |
barzolvolimab | Phase 3 | Prurigo Nodularis | - | - |
Rindopepimut (CDX-110) with GM-CSF | Phase 2 | Glioblastoma | - | - |
CDX-110 with GM-CSF | Phase 2 | Malignant Glioma | - | - |
"Investigator's Choice" chemotherapy | Phase 2 | Breast Cancer | - | - |
CDX-011 | Phase 2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | - | - |
CDX-1401 in combination with Resiquimod and/or Poly-ICLC | Phase 2 | Advanced Malignancies | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Celldex Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Celldex Therapeutics, Inc.'s (CLDX) pipeline across Phase 3, Phase 2. Its lead program is Temozolomide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celldex Therapeutics, Inc.'s next FDA catalyst?→
Celldex Therapeutics, Inc.'s (CLDX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLDX biotech catalysts?→
Add CLDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celldex Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.